Sino Biopharmaceutical Limited

Informe acción SEHK:1177

Capitalización de mercado: HK$49.1b

Dividendos de Sino Biopharmaceutical

Dividendo controles de criterios 2/6

Sino Biopharmaceutical es una empresa que paga dividendos con una rentabilidad actual de 1.97% que está bien cubierta por los beneficios. La próxima fecha de pago es en 5th July, 2024 con una fecha ex dividendo de 11th June, 2024.

Información clave

1.8%

Rentabilidad por dividendo

46%

Ratio de pago

Rentabilidad media de la industria3.6%
Próxima fecha de pago de dividendos05 Jul 24
Fecha ex dividendo11 Jun 24
Dividendo por acciónn/a
Beneficios por acciónHK$0.10
Rentabilidad por dividendo prevista a 3 años2.8%

Últimas actualizaciones de dividendos

Recent updates

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Jan 22
An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Dec 03
Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Oct 19
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

Sep 03
Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well

Aug 27
These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?

Jul 14
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?

Próximo pago de dividendos

HoyApr 25 2024Fecha ex dividendoJun 11 2024Fecha de pago de dividendosJul 05 202424 days desde ex dividendoCompra en los próximos 46 days para recibir el próximo dividendo

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: El pago de dividendos de 1177 ha sido volátil en los últimos 10 años.

Dividendo creciente: El pago de dividendos de 1177 ha aumentado en los últimos 10 años.


Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Sino Biopharmaceutical vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de 1177 con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (1177)1.8%
Suelo de mercado 25% (HK)3.4%
Techo de mercado 25% (HK)8.2%
Media de la industria (Pharmaceuticals)3.6%
Previsión de analistas en 3 años (1177)2.8%

Dividendo destacado: El dividendo de 1177(1.97%) no es notable en comparación con el 25% inferior de pagadores de dividendos del mercado Hong Kong (3.45%).

Alto dividendo: El (1.97%) del dividendo de 1177 es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Hong Kong (8.31%).


Pago de beneficios a los accionistas

Cobertura de los beneficios: Con su razonablemente bajo ratio de pago (45.5%), los pagos de dividendos de 1177 están bien cubiertos por los beneficios.


Pago en efectivo a los accionistas

Cobertura de flujo de caja: Datos insuficientes para calcular el ratio de pago en efectivo de 1177 para determinar si sus pagos de dividendos están cubiertos por los flujos de caja.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target